Rehabilitação de Síndrome de Lance-Adams: Caso Clínico

Jorge Miguel Baptista Rodrigues, Sílvia Isabel Santos Esteves Boaventura Barbosa, Susana Fernandes Rosa, Teresa Patrícia Plancha da Silva, Marta Alexandre Amaral Silva, Pedro Soares Branco

Resumo


Síndrome de Lance-Adams, ou mioclonias crónicas póshipóxia, é uma complicação rara de reanimação cardiopulmonar bem-sucedida e está geralmente associado a ataxia cerebelosa. Os autores relatam um caso de um doente de 41 anos que desenvolveu quadro clínico de disartria, tetraplegia, mioclonias severas, disdiadococinésia e ataxia cerebelosa após paragem respiratória no contexto de tratamentos de quimioterapia. Estes sintomas resultaram em consequências funcionais graves com incapacidade para o ortostatismo e para as actividades de vida diária. Foi assumido o diagnóstico de encefalopatia hipóxica com síndrome Lance-Adams. A implementação de tratamento farmacológico em conjunto com um programa interdisciplinar intensivo de reabilitação resultou em melhoria sintomática e funcional marcada permitindo a realização autónoma de actividades de vida diária e deambulação supervisionada após 7 meses. O presente artigo tem como objectivo reforçar a importância do diagnóstico correcto e tratamento adequado da síndrome de Lance-Adams, conduzindo à melhoria dos resultados funcionais destes doentes.


Palavras-chave


Mioclonia/reabilitação

Texto Completo:

PDF (English)

Referências


English WA, Giffin NJ, Nolan JP. Myoclonus after cardiac arrest: pitfalls in diagnosis and prognosis. Anaesthesia. 2009;64:908-11.

Freund B, Sutter R, Kaplan P. Lance-Adams syndrome in the pretargeted temperature management era: a case report and systematic review. Clin EEG Neurosci. 2017;48:130-8.

Gupta HV, Caviness JN. Post-hypoxic Myoclonus: Current Concepts, Neurophysiology, and Treatment. Tremor Other Hyperkinet Mov. 2016;6:409.

Zhang YX, Liu JR, Jiang B, Liu HQ, Ding MP, Song SJ, et al. Lance-Adams syndrome: a report of two cases. J Zhejiang Univ Sci B. 2007;8:715-20.

Hauw JJ, Escourolle R, Baulac M, Morel-Maroger A, Goulon M, Castaigne P. Postmortem studies on posthypoxic and post-methyl bromide intoxication: case reports. Adv Neurol. 1986;43:201–4.

Frucht S, Fahn S. The clinical spectrum of posthypoxic myoclonus. Mov Disord. 2000;15(Suppl 1):2-7.

Obrenovitch TP. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev. 2008;88:211–47.

Budhram A, Lipson D, Nesathurai S, Harvey D, Rathbone MP. Postanoxic myoclonus: two case presentations and review of medical management. Arch Phys Med Rehabil. 2014;95:588–90. doi: 10.1016/j.apmr.2013.09.008.

Matsumoto RR, Truong DD, Nguyen KD, Dang AT, Hoang TT, Vo PQ, et al. Involvement of GABA(A) receptors in myoclonus. Mov Disord. 2000;15(Suppl 1):47-52.

Welsh JP, Yuen G, Placantonakis DG, Vu TQ, Haiss F, O’Hearn E, et al. Why do Purkinje cells die so easily after global brain ischemia? Aldolase C, EAAT4, and the cerebellar contribution to posthypoxic myoclonus. Adv Neurol. 2002;89:331–59.

Polesin A, Stern M. Post-anoxic myoclonus: a case presentation and review of management in the rehabilitation setting. Brain Inj. 2006;20:213-7.

Lee HL, Lee JK. Lance-Adams syndrome. Ann Rehabil Med. 2011;35:939-43.

Frucht SJ, Trost M, Ma Y, Eidelberg D. The metabolic topography of posthypoxic myoclonus. Neurology. 2004;62:1879-81.

Hiramatsu N, Shime N, Kageyama K, Ashida H, Itoi T, Tanaka Y. Intention myoclonus in paediatric patients following severe cardiopulmonary failure: a report of three cases. Crit Care Resusc. 2002;4:104–6.

Elmer J, Rittenberger JC, Faro J, Molyneaux BJ, Popescu A, Callaway CW, et al. Clinically distinct electroencephalographic phenotypes of early myoclonus after cardiac arrest. Ann Neurol. 2016;80:175-84. doi: 10.1002/ana.24697.

De Léan J, Richardson JC, Hornykiewicz O. Beneficial effects of serotonin precursors in postanoxic action myoclonus. Neurology. 1976;26:863–8.

Rollinson RD, Gilligan BS. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate. Arch Neurol. 1979;36:44–5.

Goldberg MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology. 1976;26:24–6.

Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol. 1986;43:629–43.

Frucht SJ, Louis ED, Chuang C, Fahn S.. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57:1112-4.

Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord. 2005;11:135-7.

Asahi T, Kashiwazaki D, Dougu N, Oyama G, Takashima S, Tanaka K, et al. Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance-Adams syndrome. J Neurol. 2015;262:1581–3. doi: 10.1007/s00415-015-7748-x.

Yamada K, Sakurama T, Soyama N, Kuratsu J. Gpi pallidal stimulation for Lance-Adams syndrome. Neurology. 2011;76:1270–2.

Birthi P, Walters C, Ortiz Vargas O, Karandikar N. The use of intrathecal baclofen therapy for myoclonus in a patient with Lance Adams syndrome. PM R. 2011;3:671–3. doi: 10.1016/j.pmrj.2010.12.023.




DOI: http://dx.doi.org/10.25759/spmfr.341

Apontamentos

  • Não há apontamentos.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação